Top Stories
The combination of neoepitope-based cancer vaccine Tedopi plus Keytruda significantly improved PFS compared to best supportive care in Phase II testing.
The EMA's Committee for Medicinal Products for Human Use backed clearance of camizestrant based on progression-free survival data from the Phase III SERENA-6 study.
BIIB122 missed primary and secondary endpoints in early-stage Parkinson's disease despite strong target engagement signals.
Early efficacy signals for BioNTech/BMS's pumitamig and Pfizer's PF-08634404 sharpen competition with Summit and Akeso's drug.
Intismeran autogene plus Keytruda achieved a "landmark" recurrence-free survival rate of 68.8%.
Conference News
HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo...
ASCO: UT MD Anderson spotlights emerging precision therapies for rare and difficult-to-treat cancers22-May-2026 at 10:30 AM EDT, by The University of Texas MD Anderson Cancer Center contact patient se...
ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) Breakthrough meeting will bring together global oncology professionals in Asia to discuss the latest cancer research advances across ...
Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression CAMBRIDGE, United Kingdom, May 22, 2026 (GLOBE...
Experts also present findings on factors limiting access to cancer clinical trials22-May-2026 at 10:54 AM EDT, by Roswell Park Comprehensive Cancer Center contact patient servicesHighlightsDr. Eunice ...
